21 May 2015

Genotropin MiniQuick (Somatropin) - United Kingdom

ATC: H01AC
SYSTEMIC HORMONAL PREP EXCLUDING SEX HORMONES
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
SOMATROPIN AND SOMATROPIN AGONISTS
Genotropin MiniQuick

Generic Matches for Somatropin (6)
NutropinAq
Omnitrope
Norditropin
Zomacton
GENOTROPIN

Last Updated on 21 May 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Genotropin MiniQuick Indication

Children
Growth disturbance due to insufficient secretion of growth hormone (growth hormone deficiency, GHD) and growth disturbance associated with Turner syndrome or chronic renal insufficiency.

Growth disturbance [current height standard deviation score (SDS) < - 2.5 and parental adjusted height SDS < - 1] in short children born small for gestational age (SGA), with a birth weight and/or length below - 2 SD, who failed to show catch-up growth [height velocity (HV) SDS < 0 during the last year] by 4 years of age or later.

Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.

 

Adults
Replacement therapy in adults with pronounced growth hormone deficiency.

Adult Onset: Patients who have severe growth hormone deficiency associated with multiple hormone deficiencies as a result of known hypothalamic or pituitary pathology, and who have at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo an appropriate dynamic test in order to diagnose or exclude a growth hormone deficiency.

Childhood Onset: Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes. Patients with childhood onset GHD should be re-evaluated for growth hormone secretory capacity after completion of longitudinal growth. In patients with a high likelihood for persistent GHD, i.e. a congenital cause or GHD secondary to a pituitary/hypothalamic disease or insult, an Insulin-like Growth Factor-I (IGF-I) SDS < - 2 off growth hormone treatment for at least 4 weeks should be considered sufficient evidence of profound GHD.

All other patients will require IGF-I assay and one growth hormone stimulation test.

 

Genotropin MiniQuick Generic Name

Somatropin

Type

POM

Summary Product Characteristics (SPCs) Links
All SPC - Genotropin MiniQuick (external site)

Free Medical Education Resources

Genotropin MiniQuick Marketing Information

Genotropin MiniQuick Generic Name
Somatropin
Marketing Company
Pfizer Limited
Drug Type
POM
Date of Issue, Marketing Authority 14/09/1998

Related Drugs - Diabetes and Endocrinology

Back to top